Radar · Life Sciences in Beijing
Best Life Sciences Companies in Beijing, China
The 246 best Life Sciences companies in Beijing, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Avistone.
By Rohit KhannaTrends & Stories
246companies tracked
$4.4Bdisclosed funding
1unicorns
137have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × BEIJING
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2017median founding year
54kcombined LinkedIn audience
66%of audience held by top 3
Ranked: Best Life Sciences companies in Beijing
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Avistone Developer of precision therapeutics for oncology 32Funding top 26%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 26% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $340M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $340M | 29 mo ago | Series B | — | 2012 | — | — | — |
| 2 | Lepu Medical Technology Interventional medical devices | $316M | 70 mo ago | Public | 10,652 | 1999 | Cart FunctionalityPHPTengine+6 | — | — |
| 3 | LinkDoc 🦄 Provider of the oncology-focused database 76Moat top 15%AI top 20%Market top 25%Product top 26% All 10 signals ▾Moattop 15% AItop 20% Markettop 25% Producttop 26% Innovationtop 27% Fundingtop 31% Talentbottom 49% Globalbottom 38% Newsbottom 27% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · Unicorn AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 76/100 | $263M | 63 mo ago | Series D | 1,250 | 2014 | — | — | — |
| 4 | Geneplus Technology Developer of next-generation devices and reagents for laboratories | $220M | 58 mo ago | Series C | — | 2015 | — | — | — |
| 5 | InnoCare Developer of small molecule based therapeutics for the treatment of cancer and autoimmune disorders | $215M | 89 mo ago | Public | 1,072 | 2015 | Node.jsTailwind CSSReact+8 | — | 1 award |
| 6 | Beijing Mabworks Biotech Developer of anticancer therapies | $214M | 74 mo ago | Series C | 285 | 2003 | — | — | — |
| 7 | Sironax Developer of drugs for inflammatory and neurodegenerative diseases | $200M | 46 mo ago | Series B | — | 2017 | PHPCentOSAnimate.css+8 | 29 patents Small-molecule modulators of neurodegeneration-related enzymes and pathways | 1 partnership |
| 8 | Canbridge Life Sciences Developer of therapeutics for rare diseases and cancer | $186M | 60 mo ago | Public | 17 | 2012 | — | — | — |
| 9 | EdiGene Developer of genome editing technology for the treatment of cancer and genetic disease | $165M | 61 mo ago | Series B | 140 | 2015 | — | 103 patents Patents concentrated in chemistry & materials | — |
| 10 | Zhejiang Nuhui Health Technology Provider of early cancer screening and testing services | $152M | 71 mo ago | Public | 1,041 | 2013 | — | — | — |
| 11 | Bluepha Developer of synthetic biology and biomaterial | $133M | 40 mo ago | Series B | 120 | 2016 | — | — | — |
| 12 | CapitalBio Tech Developer of microfluidic chips for the treatment of multiple diseases | $113M | 71 mo ago | Series D | 2,000 | 2012 | — | — | — |
| 13 | Beijing Huanuotai Biomedical Technology Developer of vaccines for the treatment of infectious diseases | $104M | 26 mo ago | Series B | — | 2019 | — | — | — |
| 14 | StoneWise Provider of a software solution solution for molecular modeling | $100M | 62 mo ago | Series B | — | 2018 | — | — | — |
| 15 | Xiantong Pharmaceutical Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular… | $100M | 35 mo ago | Series E | 400 | 2004 | — | — | — |
| 16 | Pyrotech Manufacturer of therapeutics for inflammatory and oncology conditions | $97M | 24 mo ago | Series A | 10 | 2020 | — | 2 patents Innovative star-shaped glass curtain wall façade modules for architectural building envelopes. | — |
| 17 | Heyuan Biotechnology Developer of immune cell therapy drugs | $79M | 55 mo ago | Series C | — | 2018 | PHPNginxSwiper+1 | — | — |
| 18 | Luzhu Biotech Developer of human vaccines and biological drugs for multiple diseases | $73M | 47 mo ago | Public | 129 | 2001 | — | — | — |
| 19 | TowardPi Developer of OCT and optical biometers for ophthalmic diseases 55Funding top 29%Growth top 35%Market top 44%Talent bottom 49% All 6 signals ▾Fundingtop 29% Growthtop 35% Markettop 44% Talentbottom 49% Techbottom 43% Globalbottom 29% Funding: Raised $70.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $70M | 23 mo ago | Series D | 240 | 2017 | JavaBootstrapRequireJS+6 | — | 1 launch |
| 20 | Thermona Developer of RNA technology-based drugs to address various diseases | $60M | 47 mo ago | Series A | — | 2021 | — | — | — |
| 21 | Beijing Jiakesi drug development Developer of small molecule based therapeutics for cancer treatment | $55M | 93 mo ago | Public | 300 | 2015 | — | — | — |
| 22 | Murren Biotechnology Developer of microbial separation and cultivation technologies 40Moat top 22%Funding top 38%Market top 48%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 38% Markettop 48% Talentbottom 49% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $50.6M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $51M | 23 mo ago | Series C | 50 | 2015 | — | — | — |
| 23 | TCRCure Biopharma Developer of cell therapies to treat cancer | $47M | 52 mo ago | Series B | 70 | 2016 | — | 51 patents Engineered immune cell therapies with synthetic cytokine signaling and checkpoint antibodies | — |
| 24 | DeepWise Developer of AI-based radiology image solutions primarily for cancer diagnosis 72AI top 26%Funding top 30%Market top 35%Moat top 39% All 5 signals ▾AItop 26% Fundingtop 30% Markettop 35% Moattop 39% Globalbottom 36% AI: Classified as an AI company · Product described with: ai-based, deep learning Funding: Raised $46.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $46M | 16 mo ago | Series D | 200 | 2017 | — | — | — |
| 25 | Boomray Developer of radionuclide-targeted drugs for diagnosis and treatment of cancer | $43M | 45 mo ago | Series A | — | 2021 | — | 3 patents Therapeutic fibroblast activation protein (FAP) inhibitors for oncology and fibrotic disease treatment | — |
| 26 | Huaxia Yingtai Biotechnology Developer of CAR-T cell therapies for treating cancer | $38M | 56 mo ago | Series B | — | 2018 | — | — | — |
| 27 | KYinno Provider of engineered cell lines for the discovery of oncology drugs 45Funding top 34%Market top 44%Talent bottom 49%Global bottom 29% All 4 signals ▾Fundingtop 34% Markettop 44% Talentbottom 49% Globalbottom 29% Funding: Raised $35.4M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) Market: 65 employees (top 30% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 45/100 | $35M | 6 mo ago | Series B | 65 | 2017 | — | — | 1 launch |
| 28 | Hugo Biotech Developer of cloud-based pathogenic microorganism data analysis system | $34M | 68 mo ago | Series A | — | 2017 | — | — | — |
| 29 | Beijing Jinlan Gene Technology Co Developer of drugs for rare diseases by using gene technology | $31M | 36 mo ago | Series A | — | 2019 | — | — | — |
| 30 | Beijing Haosi Biotechnology Provider of services in analytical testing using mass spectroscopy | $31M | 60 mo ago | Series B | — | 2016 | — | — | — |
| 31 | Yikon Genomics Provider of NIPT and liquid biopsy tests using next-generation sequencing | $31M | 79 mo ago | Series C | 5,000 | 2012 | Element UIAnimate.cssGSAP+4 | 21 patents Patents concentrated in chemistry & materials | — |
| 32 | Beijing Zhidao Biotechnology Developer of cytokines for treating cancer | $29M | 41 mo ago | Series C | — | 2014 | — | — | — |
| 33 | BEIJING X-MAGTECH TECHNOLOGIES Developer of non-invasive magnetic resonance imaging equipment 64Funding top 32%Market top 39%Talent bottom 45%Global bottom 36% All 4 signals ▾Fundingtop 32% Markettop 39% Talentbottom 45% Globalbottom 36% Funding: Raised $28.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Market: 150 employees (top 24% of HealthTech) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 22 mo ago | Series A | 150 | 2020 | — | — | — |
| 34 | Beijing Rubber Xin Biological Technology Developer of tumor genetic testing reagents and instruments | $29M | 41 mo ago | Series B | — | 2017 | — | — | — |
| 35 | Beijing Zhongyin Technology Digital clinical genetic diagnosis tool for providers 42Funding top 41%Talent bottom 45%Global bottom 29% All 3 signals ▾Fundingtop 41% Talentbottom 45% Globalbottom 29% Funding: Raised $26.5M · 3 rounds over 5 yrs (0.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 32 mo ago | Series A | — | 2015 | — | — | — |
| 36 | Safford Decoding Provider of genetic analysis and precision medicine services | $26M | 61 mo ago | Series B | 160 | 2015 | — | — | — |
| 37 | Beijing Xinyi Biotechnology Manufacturer of micro-droplet digital PCR and in vitro diagnostic reagents | $23M | 27 mo ago | Series B | — | 2015 | — | — | — |
| 38 | Nanovision Technology Developed radioimaging equipment and accessories | $23M | 77 mo ago | Series B | 60 | 2014 | — | — | — |
| 39 | Deep Intelligent Pharma Developer of AI-based drug development platform 62Funding top 26%Talent top 28%AI top 30%Moat top 39% All 7 signals ▾Fundingtop 26% Talenttop 28% AItop 30% Moattop 39% Marketbottom 49% Techbottom 43% Globalbottom 29% Funding: Raised $21.6M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 62/100 | $22M | 4 mo ago | Series E | 100 | 2017 | Node.jsAnt DesignReact+9 | — | — |
| 40 | Pregene Provider of reagents and kits for molecular biology research | $21M | 67 mo ago | Series B | 102 | 2003 | — | — | — |
| 41 | Precision Autoimmune Therapeutics Developer of therapeutics to treat autoimmune and inflammatory diseases | $21M | 48 mo ago | Seed | — | — | — | — | — |
| 42 | Genebox Developer of genetic test kit for health and fitness | $20M | 66 mo ago | Series A | 60 | 2013 | — | — | — |
| 43 | Danyang Huichuang Medical Equipment Provider of infrared spectroscopy brain function imaging solutions | $17M | 31 mo ago | Series B | 13 | 2016 | — | — | — |
| 44 | Sino Valley Biotechnology Provider of genetic testing for canine and other pet animals | $16M | 55 mo ago | Series B | 70 | 2012 | — | — | — |
| 45 | Silexon Virtual high throughput screening based drug discovery platform | $15M | 57 mo ago | Deadpooled | — | 2018 | — | — | — |
| 46 | Beijing Youxun Medical Laboratory Provider of tests for detecting non-invasive single gene disorders, prenatal testing and tumor detection | $15M | 49 mo ago | Series B | — | 2014 | — | — | — |
| 47 | Molecular Heart Provider of chemoproteomics platform for small molecule drug discovery 24AI top 26%Funding top 38%Talent bottom 49%Tech bottom 30% All 6 signals ▾AItop 26% Fundingtop 38% Talentbottom 49% Techbottom 30% Globalbottom 29% Marketbottom 25% AI: Classified as an AI company · Product described with: ai-based, deep learning Funding: Raised $14.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $15M | 21 mo ago | Series A | — | 2022 | ReactReact RouterNginx | — | 1 launch |
| 48 | Yichao Medical Technology Provider of ultrasound equipment solutions for medical imaging | $14M | 26 mo ago | Series B | — | 2020 | — | — | — |
| 49 | TheraXyte Developer of extracellular vesicle-based drug delivery technology | $10M | 47 mo ago | Seed | — | 2019 | — | — | — |
| 50 | Novi Biotech Developer of gene therapies for cancer treatment | $7M | 31 mo ago | Series A | — | — | — | — | — |
Top 12 Life Sciences companies in Beijing
#1
Series E · Chaoyang, Beijing · founded 2017 · 100 employees$21.6Mraised▾
Series E · Chaoyang, Beijing · founded 2017 · 100 employees
Beijing Shenzhi Yao Technology is developing AI-based drug development platform. They have developed their multi-language drug development platform which provides services including drug discovery solutions, medical writing, regulatory support, electronic data acquisition system, clinical data programming, and clinical data management support. Few clients of the company include Roche, GSK, Bayer, etc.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 26%Talent
top 28%AI
top 30%Moat
top 39%Market
bottom 49%Tech
bottom 43%Funding: Raised $21.6M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Series E (Feb 2026)
Talent: Analyst team rating 4/5
AI: Classified as an AI company · Product described with: ai-based
Funding rounds
- Feb 2026Series E$60M
- Dec 2025Series D$50M
- Oct 2018Series B$15M
Investors
HSG, CDH, Xinding Capital, CITIC Capital, Jinyi Capital, Kaitai Capital Management
Tech stack
Alibaba Cloud CdnAnt DesignBaidu Analytics (百度统计)CloudflareCloudflare Bot ManagementCore-Js
#2
Series B · Beijing, Beijing · founded 2017 · 65 employees$35.4Mraised▾
Series B · Beijing, Beijing · founded 2017 · 65 employees
Provider of engineered cell lines for the discovery of oncology drugs. The service portfolio of the company includes Engineered custom cell line development, Cell-based assay, and drug screening, Antibody-drug discovery, and Cancer cell panel profiling and Biomarker discovery.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 34%Market
top 44%Talent
bottom 49%Global
bottom 29%Funding: Raised $35.4M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) · Last round Series B (Dec 2025)
Market: 65 employees (top 30% of Life Sciences)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers — 4.5% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Dec 2025Series B$35.4M
- Nov 2021Series A—
Founders & team
Investors
Matrix Partners China, Sunland Fund, Grains Valley Venture Capital, Hanne Capital, yuanshengventures, heyuanhui ventures
#3
Series D · Beijing, Beijing · founded 2017 · 200 employees$46.3Mraised▾
Series D · Beijing, Beijing · founded 2017 · 200 employees
DeepWise is a developer of AI-based radiology image solutions primarily for cancer diagnosis. Its solution uses a deep learning framework to assist in medical imaging diagnosis. Claims to help in the diagnosis of breast cancer, stroke, emergency fracture, prostate cancer, and lung cancer. The company offers the cloud-based image platform, and also helps in clinical decision making and research.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
AI
top 26%Funding
top 30%Market
top 35%Moat
top 39%Global
bottom 36%AI: Classified as an AI company · Product described with: ai-based, deep learning
Funding: Raised $46.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) · Last round Series D (Feb 2025)
Market: 200 employees (top 9% of Life Sciences)
Funding rounds
- Feb 2025Series D$68.6M
- May 2021Series C—
- Dec 2020Series C—
- Jun 2019Series C—
Investors
Sunshine Insurance Group, Beijing Changping Science and Technology Park Development, Sunland Fund, Legend Capital, Tendence Capital, Kunzhong Capital
#4
Series D · Beijing, Beijing · founded 2017 · 240 employees$70.5Mraised▾
Series D · Beijing, Beijing · founded 2017 · 240 employees
Developer of OCT and optical biometers for ophthalmic diseases. It offers devices which include endoscopic OCT, microscope, ultra-wide-field fundus camera, and others for diagnosis of ophthalmic disorders.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 29%Growth
top 35%Market
top 44%Talent
bottom 49%Tech
bottom 43%Global
bottom 29%Funding: Raised $70.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series D (Jul 2024)
Growth: Fresh capital in last 24 mo
Market: 240 employees (top 7% of Life Sciences) · Top-10,000,000 web property
Audience (LinkedIn): 4k LinkedIn followers — 8.2% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jul 2024Series D$27.5M
- Dec 2022Series D$43M
Founders & team
Investors
Matrix Partners China, ShenZhen GTJA Investment Group
Tech stack
Core-JsGsapJqueryJquery UiOpen GraphPriority Hints
#5
Series C · Beijing, Beijing · founded 2015 · 50 employees$50.6Mraised▾
Series C · Beijing, Beijing · founded 2015 · 50 employees
Developer of microbial separation and cultivation technologies. It has developed Eco-screening TM technology, fungal high-density solid fermentation technology foroxygen, H2O, pH value, carbon, & nitrogen source, and microfilm coating technology on the surface of seeds to stop the damage of microorganisms. It has applications in biological agriculture, human microbiome research biomedicine, and gene discovery.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 38%Market
top 48%Talent
bottom 49%Global
bottom 29%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $50.6M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) · Last round Series C (Jul 2024)
Market: 50 employees (top 36% of Life Sciences)
Funding rounds
- Jul 2024Series C$41.3M
- Feb 2020Series B—
- Jun 2018Seed$9.3M
Founders & team
Investors
Guangzhou Yuexiu Industrial Investment Fund Management, SDIC, Highlight Capital, Longmen Capital
#6
Series B · Beijing, Beijing · founded 2012$340Mraised▾
Series B · Beijing, Beijing · founded 2012
Developer of precision therapeutics for oncology. It offers a lead compound PLB1004, a novel mono-anilino-pyrimidine small molecule inhibitor of EGFRa that has anti-tumour effect.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 26%Moat
top 38%Talent
bottom 49%Market
bottom 37%Global
bottom 36%Funding: Raised $340M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Dec 2023)
Moat: Editorial + unicorn rating 4/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Dec 2023Series B$140M
- Dec 2021Series A$200M
Founders & team
Investors
IDG Capital, Yanchuang Capital, Cathay Capital, Bain Capital, SDIC, Vivo Capital
#7
Series A · Haidian, Beijing · founded 2020 · 150 employees$28.7Mraised▾
Series A · Haidian, Beijing · founded 2020 · 150 employees
Developer of non-invasive magnetic resonance imaging equipment. The company offers a liquid-free helium magnetocardiography that detects the weak magnetic field for large-scale cardiovascular functional imaging.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 32%Market
top 39%Talent
bottom 45%Global
bottom 36%Funding: Raised $28.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series A (Jul 2024)
Market: 150 employees (top 24% of HealthTech)
Talent: 1 named leader on record
Funding rounds
- Jul 2024Series A$13.8M
- Jun 2022Series A$15M
Founders & team
Investors
IDG Capital, Langmafeng Venture Capital, Yarui Capital, CMBC Capital, Zgcity.com, Zhongke Chuangxing
#8
Series A · Beijing, Beijing · founded 2020 · 10 employees$96.9Mraised▾
Series A · Beijing, Beijing · founded 2020 · 10 employees
Manufacturer of therapeutics for inflammatory and oncology conditions. The company develops small molecule and biologic immunomodulators to advance clinical studies and the pipeline for inflammation-related diseases as diverse as cancer, sepsis and Alzheimer’s.
Funding rounds
- May 2024Series A—
- Jul 2023Series A$96.9M
Founders & team
Investors
SDIC Venture Capital Management, China Venture Capital, China Taiping Insurance Group, Frees Fund, Lotus Lake Capital Management, Fengrui Capital
#9
Series B · Beijing, Beijing · founded 2019$104.4Mraised▾
Series B · Beijing, Beijing · founded 2019
Developer of vaccines for the treatment of infectious diseases. The company specializes in the development and industrialization of human vaccine products and innovative adjuvants for COVID-19, influenza, malaria and herpes zoster.
Funding rounds
- Mar 2024Series B$84M
- Mar 2021Series A$20.4M
Founders & team
Investors
Fontus Capital, 3E BioVentures, Huayin Financial Investment, Watere Capital, Shunxi Venture Capital
#10
Series A · Beijing, Beijing · founded 2022$14.6Mraised▾
Series A · Beijing, Beijing · founded 2022
Provider of chemoproteomics platform for small molecule drug discovery. The company has created an AI-based macromolecular optimization and design platform "MoleculeOS" with uses data-driven deep learning methods to help biotechnologists quickly identify and generate the most suitable proteins and rapidly project laboratory research results on a large scale for industrial applications.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
AI
top 26%Funding
top 38%Talent
bottom 49%Tech
bottom 30%Global
bottom 29%Market
bottom 25%AI: Classified as an AI company · Product described with: ai-based, deep learning
Funding: Raised $14.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) · Last round Series A (Sep 2024)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 515 LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Sep 2024Series A—
- Feb 2023Angel$14.6M
Founders & team
Investors
Cathay Biotech, Sequoia Capital China, Lenovo Capital and Incubator Group, Shenzhen Capital Group, Cher Ami, SenseCapital
Tech stack
NginxReactReact Router
#11
Series B · Beijing, Beijing · founded 2016 · 120 employees$133Mraised▾
Series B · Beijing, Beijing · founded 2016 · 120 employees
Developer of synthetic biology and biomaterial. The company has microbial manufacturing technology that helps in developing bio-based products for a broad range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics, and more
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers — 4.3% of this cohort's audience
Funding rounds
- Feb 2023Conventional Debt$73.3M
- Feb 2023Series B$58.6M
- Jan 2022Series B—
- Aug 2021Series B$66.4M
Investors
Frees Fund, Qianhai Ark Asset Management, Hillhouse, SANY Group, Fujian Septwolves Industry, Lightspeed Venture Partners
#12
Series E · Beijing, Beijing · founded 2004 · 400 employees$99.5Mraised▾
Series E · Beijing, Beijing · founded 2004 · 400 employees
Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents.
Funding rounds
- Jul 2023Series E—
- Oct 2021Series D$50M
- Feb 2021Series D$49.5M
Investors
SDIC, Goldstone Investment, National Research Fund, General Technology Venture Capital, CITIC, Langmafeng Venture Capital
Funding & investor landscape
$4.4Btotal disclosed funding
89companies funded
140disclosed rounds
0rounds last 90 days
Most active investors
Qiming Venture Partners14 rounds
Notable founders
Hao Feng
Co-Founder & Director · KYinno
Yingqi Wang
CEO · TowardPi
Jiang Xianzhi
Founder & CEO · Murren Biotechnology
Shi Hepeng
Founder & CEO · Avistone
Bin Cai
Founder & CEO · BEIJING X-MAGTECH TECHNOLOGIES
TJ Deng
Co-Founder & CEO · Pyrotech
Feng Shao
Co-Founder · Pyrotech
Wang Hailong
CEO · Beijing Huanuotai Biomedical Technology
Xu Jinbo
Founder · Molecular Heart
Zhiyuan Zhang
Co-Founder · Sironax
Xiaodong Wang
Co-Founder · Sironax
Yi Xin
Co-Founder & CEO · Geneplus Technology
Prism market signals · China · country-scoped Prism corpus, 217,045 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN BEIJING · Health & Bio
How research on Biotechnology in Beijing is moving
A read on the academic research around Biotechnology in Beijing — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 276 papers.
Beijing's institutions—led by Beijing Academy of Agricultural and Forestry Sciences and Beijing Forestry University—predominantly research plant molecular biology and gene expression, with biosensing techniques emerging, in an optimistic tone.
276 papers · stance +0.52 · 45% breakthrough · 16% concern
top institutions
- Beijing Academy of Agricultural and Forestry Sciences31
- Beijing Technology and Business University30
- Beijing Forestry University19
- Beijing University of Chemical Technology18
- Beijing University of Agriculture16
leading researchers
Jing Wang · Baojun Xu · Bingyu Chen · Haochen Lyu · Xi Chen · Xiaoting Feng
prism intelligence · tone & topics
95% positive · 3% critical tone
HealthAgriculturePharmaceuticalsMedical ResearchBiologyGenetics
▲
Breakthroughs111 · 40%
▼ 61%→38% share
▼0.6× share momentum0 median citations86% since 2021mostly methods-led
Gene research newly dominates breakthroughs with 10 papers as transcription factor studies surged 1→7.
rising sub-themes (early→recent)
- Transcription factor1→7
- Transcriptome1→5
- Mutant1→3
- Transcription (linguistics)1→3
- Cleavage (geology)1→3
Newly emergingGene 0→10 · Biodistribution 0→4 · Identification (biology) 0→4
Landmark Graphene in Mice: Ultrahigh In Vivo Tumor Uptake and Efficient Photothermal Therapy · 2,383 cites
◆
Advancements97 · 35%
▲ 22%→36% share
▲1.6× share momentum0 median citations94% since 2021mostly empirical
Metabolomics, Agriculture, and Fermentation all emerged brand-new, driving advancements' field-share from 22%→36%.
rising sub-themes (early→recent)
- Metabolomics8
- Agriculture7
- Fermentation6
- Gene5
- Production (economics)5
Newly emergingMetabolomics 0→8 · Agriculture 0→7 · Fermentation 0→6
Landmark Automatic Image-Based Plant Disease Severity Estimation Using Deep Learning · 716 cites
▼
Concerns40 · 14%
▲ 6%→16% share
▲2.7× share momentum0 median citations98% since 2021mostly reviews
Food safety and Agriculture concerns newly emerged as concern field-share intensified from 6%→16%.
rising sub-themes (early→recent)
- Key (lock)4
- Food safety3
- Agriculture3
- Human health3
- Drug development3
Newly emergingKey (lock) 0→4 · Food safety 0→3 · Agriculture 0→3
Landmark Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies · 2,066 cites
Common questions
How many Life Sciences companies are there in Beijing, China?
Radar tracks 246 indexable Life Sciences companies headquartered in Beijing, China that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Beijing, China?
The Life Sciences companies in Beijing, China on this list have raised a combined $4.4B in disclosed equity funding across 89 funded companies.
Which is the highest-funded Life Sciences company in Beijing, China?
Avistone is the highest-funded Life Sciences company in Beijing, China, with $340M in disclosed equity funding.
How many Life Sciences companies in Beijing, China are funded?
89 of the 246 Life Sciences companies in Beijing, China on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Beijing, China?
1 Life Sciences company in Beijing, China on this list is valued at $1B or more.
Who are the top investors in Beijing, China Life Sciences companies?
The most active investors in Beijing, China Life Sciences companies on this list include Qiming Venture Partners, Lotus Lake Capital Management, Legend Capital, THG Ventures, CD Capital.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.